Valuation: ZIM Laboratories Limited

Market Cap 6.3B 65.67M 57.73M 53.74M 49.35M 92.67M 93.89M 639M 249M 3.11B 247M 241M 10.75B P/E 2025
32.1x
P/E 2026 50.3x
Enterprise Value 7.16B 74.67M 65.64M 61.1M 56.11M 105M 107M 726M 284M 3.54B 280M 274M 12.22B EV / Sales 2025
1.34x
EV / Sales 2026 1.09x
Free-Float
28.79%
Yield 2025 *
-
Yield 2026 -
1 day-2.00%
1 week-6.26%
Current month-5.39%
1 month-5.05%
3 months+40.77%
6 months+65.10%
Current year+63.58%
1 week 117.6
Extreme 117.6
122.5
1 month 111.5
Extreme 111.5
126.3
Current year 59.72
Extreme 59.72
133.95
1 year 59.72
Extreme 59.72
133.95
3 years 59.72
Extreme 59.72
151.75
5 years 36.37
Extreme 36.3667
151.75
10 years 14
Extreme 14
151.75
Manager TitleAgeSince
Chief Executive Officer - 2001-12-31
Director of Finance/CFO - 2019-03-31
Director of Finance/CFO - 1990-12-31
Director TitleAgeSince
Chairman - 1989-12-31
Director/Board Member - 1990-12-31
Director/Board Member - 2012-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-2.00%-6.26%+3.38%+3.75% 66.73M
+1.68%+2.13%+16.17%+77.49% 48.36B
+1.52%+2.95%+60.39%+112.28% 35.8B
-0.09%-0.66%-8.03%+31.90% 11.83B
-0.05%-3.10%+13.50%+77.95% 11.48B
+0.56%-0.37%+37.53%+142.08% 9.01B
+0.18%+0.58%+49.62%-9.13% 6.99B
+0.95%-2.00%+12.78%+32.58% 6.7B
+0.18%-1.77%+2.36%+172.36% 6.42B
+3.51%-10.57%-31.55%+0.09% 5.3B
Average +0.64%-1.52%+15.61%+64.14% 14.2B
Weighted average by Cap. +1.17%-0.15%+25.52%+81.59%

Financials

2025 2026
Net sales 3.79B 39.53M 34.75M 32.35M 29.71M 55.79M 56.53M 385M 150M 1.87B 148M 145M 6.47B 3.74B 39.04M 34.32M 31.95M 29.34M 55.09M 55.82M 380M 148M 1.85B 147M 143M 6.39B
Net income 122M 1.27M 1.12M 1.04M 953K 1.79M 1.81M 12.34M 4.82M 60.07M 4.76M 4.66M 208M 58.38M 609K 535K 498K 458K 859K 870K 5.92M 2.31M 28.83M 2.29M 2.24M 99.64M
Net Debt 1.16B 12.07M 10.61M 9.88M 9.07M 17.04M 17.26M 117M 45.86M 572M 45.31M 44.34M 1.98B 863M 9M 7.91M 7.36M 6.76M 12.7M 12.87M 87.54M 34.19M 426M 33.78M 33.06M 1.47B
Logo ZIM Laboratories Limited
ZIM Laboratories Limited is a pharmaceutical company. The Company develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. Its delivery solutions cover product conceptualization product development, filing for registration, manufacture, and supply of various pharmaceutical formulations. It is developing products in various therapeutic segments like, central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology and vitamins, minerals, and dietary supplements. Its technological capabilities include drug release modification, solubility and stability enhancement, taste masking and dosage form transformation. Its product offerings include finished formulations and pre-formulations intermediates, which include granules, pellets, taste-masked powders, dry suspensions, tablets, capsules, and oral thin films.
Employees
632
Date Price Change Volume
26-07-27 117.60 -2.00% 995
26-07-24 ₹120.00 -0.04% 2,214
26-07-23 ₹120.05 -2.00% 500
26-07-21 ₹122.50 -2.00% 400
26-07-20 ₹125.00 -0.36% 2,296
  1. Stock Market
  2. Stocks
  3. ZIMLAB Stock